iiinova — where your digital self keeps evolving

PAREA @pareascience.bsky.social · 15/07/2026

US agencies are moving fast on psychedelic therapies: clinical guidance, regulatory readiness, cross-agency work, following April's EO on mental health and ARPA-H's $100M moonshot. Europe shouldn't wait. PAREA wants mental health reflected across the EU Biotech Act. tinyurl.com/parea-news

010

PAREA @pareascience.bsky.social · 30/06/2026

🚨 The June EU Insights newsletter is out 🚨 Highlights: • PAREA's Biotech Act recommendations to the European Commission. • Updates from the European Academy of Neurology Congress. • PsyPal trial expansion across Europe. • Francisca Silva speaking at PSY-NET during FENS. Read more: lnkd.in/dc3RXaAd

000

PAREA @pareascience.bsky.social · 16/06/2026

We're pleased to welcome Psychedelic Lived Experiences as PAREA's newest Community Supporter! They elevate patient voices in psychedelic care through advocacy, education, and community because lived experience is genuine expertise. Learn more: parea.eu/parea-news/p...

000

PAREA @pareascience.bsky.social · 12/06/2026

We submitted our response to the European Commission’s consultation on the EU4Health 2027 Work Programme. We call for stronger health systems to address NCDs, with mental health as a core priority, alongside support for workforce development, implementation, and access to care. lnkd.in/dSQJauZh

000

PAREA @pareascience.bsky.social · 26/05/2026

PAREA has submitted recommendations to the EU Commission’s upcoming Biotech Act consultation, calling for mental health innovation to be included in Europe’s biotech strategy. Mental health innovation is both a public health priority and a competitiveness opportunity for Europe. lnkd.in/ee6cEgb8

000

PAREA @pareascience.bsky.social · 21/04/2026

France expands access to ketamine for patients in suicidal crisis. A 3 year programme allows IV racemic ketamine for adults with acute suicidal ideation, prescribed by psychiatrists and delivered in hospitals. Based on strong evidence and lower cost compared to esketamine. parea.eu/parea-news/f...

010

PAREA @pareascience.bsky.social · 31/03/2026

At the EPA Congress in Prague, PAREA engaged with clinicians and professionals on the role of psychedelic therapies in mental health care. Strong turnout for David Nutt’s sessions reflects growing interest in moving these approaches into clinical practice. More here: tinyurl.com/parea-at-the...

000

PAREA @pareascience.bsky.social · 30/03/2026

Today marks the launch of a new PsyPal guidance paper on how to standardise and implement psychedelic therapies in Europe. PAREA contributed to this work alongside partners in the PsyPal consortium. It outlines practical steps for moving toward real-world integration. tinyurl.com/psypal-guida...

000

PAREA @pareascience.bsky.social · 25/03/2026

PAREA is co-organising a webinar on the EU-funded PsyPal project, exploring psilocybin-assisted therapy for psychological distress in palliative care, incl. neurological conditions. 13 April, 14:00 to 15:30 CEST, with the EU Health Policy Platform. Register here: tinyurl.com/psypal-webinar

010

PAREA @pareascience.bsky.social · 23/03/2026

PAREA will be at the European Psychiatric Association Congress in Prague, 28–31 March. We will be hosting a stand to engage with the psychiatric community on the current status and potential of psychedelic therapies. Find us at our stand in the exhibition hall! More info: parea.eu/events/parea...

000

PAREA @pareascience.bsky.social · 20/03/2026

A psychedelic compound, bretisilocin, has entered the EMA PRIME scheme for major depressive disorder. PRIME supports high need medicines through early regulatory engagement, marking a meaningful step for Europe’s role in mental health innovation. Read more: tinyurl.com/news-release...

110

PAREA @pareascience.bsky.social · 18/03/2026

Webinar on legal pathways for psychedelic therapies in Europe, March 20 at 18:00 CET. PAREA joins UPRA and Ukraine’s Public Health Centre, with Marion Haberkamp, João Taborda da Gama, and Pavel Pachta. Register here: parea.eu/events/webin...

000

PAREA @pareascience.bsky.social · 17/03/2026

Join our European Parliament event on psychedelic research and access for war related mental health needs in Ukraine, including PTSD among veterans. 6 May 2026, 14:30 to 16:30, Brussels and online Register here: parea.eu/events/psych...

101

PAREA @pareascience.bsky.social · 09/03/2026

We welcome HYSTELICA as PAREA’s newest Community Supporter! The nonprofit advances psychedelic science for women through research, advocacy, and education. They focus on how psychedelics interact with female biology and closing gaps in women’s health research. More here: tinyurl.com/hystelica

010

PAREA @pareascience.bsky.social · 18/02/2026

Compass Pathways released topline data from its second Phase 3 trial of COMP360 psilocybin in treatment resistant depression. In COMP006 (n=581), two 25 mg doses showed a -3.8 MADRS difference vs 1 mg at Week 6. Prior Phase 3 data showed -3.6 vs placebo. More: tinyurl.com/readout-for-...

000

PAREA @pareascience.bsky.social · 17/02/2026

Spain’s Parliament hosted its first conference on psychedelic assisted psychotherapies on February 13. Clinicians, researchers, and regulators focused on evidence, responsible training, and equity in access. The debate has now formally entered the legislative arena. Learn more: tinyurl.com/spain-pap

010

PAREA @pareascience.bsky.social · 16/01/2026

PAREA submitted feedback on the European Commission’s ERA Act consultation, urging mental health as a strategic R&I priority and better coordinated funding that protects scientific freedom and speeds translation into practice. Learn more: parea.eu/parea-news/p...

000

PAREA @pareascience.bsky.social · 16/12/2025

EU institutions have agreed on the 1st major revision of pharmaceutical legislation in 20 years, reshaping incentives, access rules, and introducing regulatory sandboxes. PAREA will keep pushing for mental health to be recognised as the package moves forward. Learn more: tinyurl.com/pharma-legis...

010

PAREA @pareascience.bsky.social · 09/12/2025

New article maps key regulatory and clinical hurdles for bringing psychedelic therapies into EU healthcare. It underlines HTA as the decisive barrier and notes psychotherapy + pharmacotherapy as the gold standard, raising questions for assessing added value. More details: tinyurl.com/therapy-path...

tinyurl.com

What Europe’s health systems will require to implement psychedelic therapies — PAREA

A new article published in European Neuropsychopharmacology provides a critical assessment of what psychedelic therapi es would need in order to be integrated into European healthcare systems. ...

010

PAREA @pareascience.bsky.social · 27/11/2025

PAREA will join the PSYCH Symposium in London on Dec 4. Our Project Officer, Francisca Silva, will speak on integrating psychedelic medicines into healthcare alongside the MIND Foundation, Dr Liliana Galindo and Jeff Smith MP. Learn more about the conference here: www.psychsymposium.com/agenda

010

PAREA @pareascience.bsky.social · 24/11/2025

The US just launched EVIDENT, a 100M mental health moonshot days after PAREA called for a mission driven mental health moonshot in Europe. Neuroplastogens included. Clear signal that mental health innovation is going strategic. Europe has a window to lead. Learn more: parea.eu/parea-news/1...

000

PAREA @pareascience.bsky.social · 19/11/2025

Mental health innovation is rising in Europe and PAREA is at the centre. From calling for a European Mental Health Moonshot to EU-backed psychedelic trials, new members, major policy input, and the PsyPal trial now recruiting. Read the full newsletter: view.flodesk.com/emails/691d8...

000

PAREA @pareascience.bsky.social · 12/11/2025

PAREA welcomes the Women’s Brain Foundation as a new full member. Together, we’re pushing for sex and gender differences to be systematically recognised in mental health and psychedelic research, policy, and innovation across Europe. Learn more: view.flodesk.com/emails/6911d...

000

PAREA @pareascience.bsky.social · 07/11/2025

PAREA is partnering with the HoloMind: Psychedelic Therapy and Integration Conference 2025, Nov 15–16 in Warsaw and online. Experts will explore how psychedelics can help treat depression, PTSD, and addiction, and how Europe can connect evidence, ethics, and practice. holomind.org/en/2nd-editi...

010

PAREA @pareascience.bsky.social · 24/10/2025

We’re proud to support the first-ever Psychedelic Lived Experiences Summit! Nov 21-23| Free & Virtual This event bridges science and lived experience to explore psychedelic healing with 50+ speakers including patients, clinicians & researchers. 🎟️ Register: psychedeliclivedexperiences.com/summit

000

PAREA @pareascience.bsky.social · 23/10/2025

Our Project Officer Francisca Silva will represent PAREA at IMBAS 2025 – Ireland’s leading psychedelic research conference, Oct 31–Nov 1 at Trinity College Dublin. She'll share a EU perspective on the landscape of psychedelic therapies’ development and integration in healthcare. www.idpat.ie/events

020

PAREA @pareascience.bsky.social · 17/10/2025

The ALPS Awareness Lectures on Psychedelic Science return to Geneva on 24–25 October at Campus Biotech. Hosted by the ALPS Foundation, PAREA’s community supporter, the event showcases the latest expertise in psychedelic science and therapy. Learn more: www.alpsconference.com

000

PAREA @pareascience.bsky.social · 10/10/2025

To mark #WorldMentalHealthDay, PAREA contributed feedback to the EU’s next long-term budget. Our message: make mental health central to Europe’s innovation agenda. We call for decisive action to ensure the next generation of mental health treatments are accessible to all who need them.

010

PAREA @pareascience.bsky.social · 02/10/2025

Mental health conditions cause more years of ill-health than cancer, diabetes & heart disease combined, yet innovation has stalled. Join us 4 November in Brussels & online for our hybrid event, exploring how Europe can go from lagging to leading in mental health innovation. parea.eu/events/nov4

000

PAREA @pareascience.bsky.social · 30/09/2025

The EMA’s updated guideline on depression treatment takes effect today, with a dedicated section on psychedelics. PAREA contributed >10 comments during consultation, many of which shaped the final text. See the revised guideline here: tinyurl.com/ema-gl

000

PAREA @pareascience.bsky.social · 22/09/2025

Pain Alliance Europe (PAE), has launched an important EU-wide survey exploring the links between chronic pain, mental health, and self-management. The findings will inform advocacy efforts and shape better policies for people living with chronic pain across Europe. lnkd.in/dv2vd7CC

010

PAREA @pareascience.bsky.social · 16/09/2025

Buenos Aires will host LaPsyConf, an international conference on mental health, longevity, and well-being. Tadeusz Hawrot opens with Global Issues: Mental Health Indicators, Global Regulation, and Economic Impact. Get 10% off with code PAREA. Register: www.lapsyconf.com

000

PAREA @pareascience.bsky.social · 12/09/2025

On Oct 1 in Lisbon, following the @psypaleu.bsky.social General Assembly, PAREA will join EU at @champalimaudf.bsky.social stakeholders for a full-day symposium focused on the ethical, regulatory & clinical dimensions of psychedelic-assisted care. Learn more & register: tinyurl.com/8h2jnup

010

PAREA @pareascience.bsky.social · 10/09/2025

On this World Suicide Prevention Day, PAREA supports the call to change the narrative on suicide, moving from stigma and silence to openness, understanding, and support. Together, prevention is possible. @iaspinfo.bsky.social

000

PAREA @pareascience.bsky.social · 09/09/2025

We’re pleased to support the upcoming Borealis Psychedelic Science Summit, a two-day scientific conference taking place in Stockholm on September 26–27, as a Community Partner. Learn more and register here: borealissummit.com

000

PAREA @pareascience.bsky.social · 03/09/2025

The WHO just released two reports on mental health. They show more than 1B people live with a disorder, while governments’ spending has barely moved since 2017. Europe leads at $51.76 per person, the Americas just $6.86. Disorders keep rising, but investment hasn’t. 🔗 lnkd.in/dW_NU3VA

000

PAREA @pareascience.bsky.social · 01/09/2025

PAREA is partnering with Inawe Foundation for Psymposium Madrid 2025, Oct 2–4. The conference features leading experts in mental health, neuroscience, and psychedelics, and our community receives 10% off tickets with code PSYMP0S1UM2025. More here: tinyurl.com/parea-psympo...

020

PAREA @pareascience.bsky.social · 28/08/2025

The Dutch Medicines Evaluation Board will host a Pipeline Meeting on 5 Nov 2025, focusing on the regulatory development of psychedelics. Pharmaceutical companies can apply to present and discuss psychedelic development challenges with Dutch regulators. Deadline: 29 Aug tinyurl.com/meb-pipeline...

001

PAREA @pareascience.bsky.social · 27/08/2025

Norway just took a big step in mental health: its regulator will reimburse off-label generic IV ketamine for treatment-resistant depression paired with psychotherapy. Backed by a positive HTA, years of protocolized use, and NORAAD’s €2.2m study. First in Europe. More: tinyurl.com/norway-ketam...

000

PAREA @pareascience.bsky.social · 15/08/2025

PAREA has submitted its contribution to the EU’s EU4Health 2026 consultation. Our key message: mental health innovation must become a strategic and structural priority for EU health policy. The consultation is open until 30 September 2025. Our full contribution is available here: lnkd.in/dECfeG5d

000

PAREA @pareascience.bsky.social · 11/08/2025

PsyPal just enrolled its first patient in the EU’s first multi-site trial of psilocybin therapy for palliative care beyond cancer. 100+ patients, 4 sites, 1 historic step for mental health in Europe. Read the full press release here: tinyurl.com/psypal-augus...

010

PAREA @pareascience.bsky.social · 31/07/2025

Germany becomes the first EU country to approve compassionate use of psychedelic therapy. Patients who haven’t responded to conventional depression treatments can now access it at CIMH and the OVID Clinic. A major step toward broader access to psychedelic care in Europe! tinyurl.com/compassionat...

030

PAREA @pareascience.bsky.social · 21/07/2025

We’re happy to welcome Irish Doctors for Psychedelic Assisted Therapy as the newest member of PAREA’s Community Supporters network. This fall, PAREA will join the Psychedelic Research Conference, co-hosted by IDPAT and Trinity College Dublin. More here: tinyurl.com/idpat

010

PAREA @pareascience.bsky.social · 15/07/2025

Big news for psychedelic research in Europe: The new €4.3M INTEGRATE project will train 16 PhDs across Europe. Funded by Marie Skłodowska-Curie Actions, it marks a major step forward. PAREA is proud to support by hosting secondments. More here: parea.eu/parea-news/i...

parea.eu

Europe Invests in the Future of Psychedelic Science: INTEGRATE Doctoral Network Launches with €4.3 Million in Funding — PAREA

A second major EU-funded project in psychedelic science, following PsyPal, will start in the coming months. INTEGRATE will be a doctoral training network supported by €4.3 million in EU funding throug...

054

PAREA @pareascience.bsky.social · 15/07/2025

A new expert commentary published on The Mental Elf outlines five priorities to advance psychedelic mental health care. Co-authored by leading voices across sectors, it reflects growing momentum. PAREA is pleased to have contributed input. Learn out more about it here: parea.eu/parea-news/i...

parea.eu

New expert commentary outlines five priorities to advance psychedelic therapies in mental health care — PAREA

A new expert commentary is outlining five priorities to advance psychedelic therapies in mental health care. Published on The Mental Elf—an online resource on mental health research— the piece follow...

030

PAREA @pareascience.bsky.social · 15/07/2025

Big news: PAREA just received a €50K grant from Entheon Foundation to strengthen EU advocacy, push for more funding, and build capacity for psychedelic-assisted mental health treatments across Europe. Thanks to Entheon for backing this work! Read more here: parea.eu/parea-news/e...

000

PAREA @pareascience.bsky.social · 01/07/2025

PAREA is delighted to welcome Nico Gusac to our team as our new Communications Officer! With a multidisciplinary background and a deep commitment to mental health, culture, and ethics, Nico is passionate about healing as a relational and systemic process, convinced that community is medicine.

050

PAREA @pareascience.bsky.social · 30/06/2025

Today, the EU4Health Civil Society Alliance launched Health4Europe: a blueprint for the next EU Health Programme. As a proud member, PAREA endorses this call to keep health a top EU priority in the next MFF. Read the full proposal here: tinyurl.com/eu4healthblueprint

000

PAREA @pareascience.bsky.social · 27/06/2025

On February 26, 2025, during the Psychedelics as Medicine conference in Reykjavik, Iceland, representatives from all Nordic psychedelic associations signed the Manifesto for the Nordic Psychedelic Network Initiative. Learn more in our latest guest article by Cecilie Byholt Endresen: bit.ly/3TOXmyg

021

PAREA @pareascience.bsky.social · 24/06/2025

We’re proud to be representing the PsyPal project @psypaleu.bsky.social at Psychedelic Science, in Denver, and at the European Academy of Neurology Congress, in Helsinki!

032